MAHTAB MOLLAJAFAR: Open Payments
NPI 1659836799 · FAIRFAX STATION, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,742 in 49 payments from 11 companies in 2025. Trend: 2023 $751 · 2024 $1,088 · 2025 $1,742
Food & beverage: $1,742
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $586 |
| MERZ NORTH AMERICA, INC. | 9 | $568 |
| Novo Nordisk Inc | 6 | $159 |
| Galderma Laboratories, L.P. | 2 | $138 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $93 |
| Neuronetics, Inc. | 2 | $49 |
| Daiichi Sankyo Inc. | 2 | $43 |
| AstraZeneca Pharmaceuticals LP | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Biogen, Inc. | 1 | $22 |
Products named: BOTOX, Xeomin, CAPLYTA, Wegovy, Ozempic, NEUROSTAR TMS THERAPY SYSTEM, INJECTAFER, FARXIGA.
Industry payments across VA — which companies pay providers there.
